Mechanisms of acute respiratory distress syndrome: Role of surfactant changes and mechanical ventilation

Journal of Physiology and Pharmacology

Volumn 48, Issue 4, 1997, Pages 537-557

  Verbrugge, S J C ^a   Sorm V ^a   Lachmann, B ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Acute respiratory distress syndrome; Alreolo capillary barrier; Bacterial translocation; Multiple organ failure; Positive end expiratory pressure

Indexed keywords

SURFACTANT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; BACTERIAL TRANSLOCATION; CONFERENCE PAPER; LUNG ALVEOLUS; LUNG DIFFUSION; LUNG EDEMA; LUNG INJURY; LUNG PARENCHYMA; LUNG VENTILATION; MULTIPLE ORGAN FAILURE; POSITIVE END EXPIRATORY PRESSURE;

HUMANS; LUNG; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 2642703429     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (91)

1. Bernard GR, Artigas A, Brigham KL et al. The American-European consensus conference on ARDS: definitions, mechanica, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824.
2. Repine JE. Scientific perspectives on adult respiratory distress syndrome. Lancet 1992; 339: 466-469.
3. Holm BA. Surfacant inactivation in adult respiratory distress syndrome. In Pulmonary surfactant B Robertson, LMG van Golde, JJ Batenburg (eds.) Amsterdam Elsevier, 1992: 665-684.
4. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 319-323.
5. Krafft P, Fridrich P, Perner ST et al. The acute respiratory distress syndrome: definitions, severity and clinical outcome. Int Care Med 1996; 22: 519-525.
6. Montgomery AB, Stager MA, Carrico J, Hudson LD. Causes of mortality in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132: 485-489.
7. Villar J, Manzano J, Blazquez M et al. Multiple system organ failure in acute respiratory failure. J Crit Care 1991; 6: 75-80.
8. Demling RH. Adult respiratory distress syndrome: Current concepts. New Horizons 1993; 1: 388-401.
9. Amato MBP, Barbas CSV, Medeiros D et al. Improved survival in ARDS: beneficial effects of a lung protective strategy. Am Rev Respir Crit Care Med 1996; 153: A531.
10. Houmes RJ, Bos JAH, Lachmann B. Effects of different ventilator settings on lung mechanics: with special reference to the surfactant system. Appl Cardiopulm Pathophysiol 1994; 5: 117-127.
11. Seeger W, Günther A, Walmrath HD, Grimminger F, Lasch HG. Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects. Clin Investig 1993; 71: 177-190.
12. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Resp Dis 1993; 147: 218-233.
13. Veldhuizen RAW, Inchley K, Hearn SA, Lewis JF, Possmayer F. Degradation of surfactant associated protein B (SP-B) during in vitro conversion of large into small surfactant aggregates. Biochem J 1993; 295: 141-147.
14. Magoon MW, Wright JR, Baritussio A et al. Subfractions of lung surfactant. Implications for metabolism and surface activity. Biochem Biophys Acta 1983; 750: 18-31.
15. Wright JR, Benson BJ, Williams MC, Goerke J, Clements JA. Protein composition of rabbit alveolar surfactant subfractions. Biochim Biophys Acta 1984; 791: 320-332.
16. Yamada T, Ikegami M, Jobe AH. Effects of surfactant subfractions on preterm rabbit lung function. Pediatr Res 1990; 27: 592-598.
17. Veldhuizen RAW, McCraig LA, Akino T, Lewis JF. Pulmonary subfractions in patients with the acute respiratory distress syndrome. Am J Resp Crit Care Med 1995; 152: 1867-1871.
18. Gregory T, Longmore W, Moxley M et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 65: 1976-1981.
19. Mead J, Takishima T, Leith D. Stress distribution in lungs: a model of pulmonary elasticity. J Appl Physiol 1970; 28: 596-608.
20. Lachmann B. Open up the lung and keep the lung open. Intens Care Med 1992; 18: 319-321.
21. Muscerede JG, Mullen JBM, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am J Resp Crit Care Med 1994; 149: 1327-1334.
22. John TV, Evander E, Robertson B, Jonson B. Sufactant dysfunction makes lung vulnerable to repetitive collapse and reexpansion. Am J Resp Crit Care Med 1997; 155: 313-320.
23. Nilsson R, Grossman G, Robertson B. Pathogenesis of neonatal lung lesions induced by artificial ventilation: evidence against the role of barotrauma. Respiration 1980; 40: 218-225.
24. Mead J, Collier C. Relation of volume history of lungs to respiratory mechanics in anesthetized dogs. J Appl Physiol 1959; 14: 669-678.
25. Greenfield LJ, Ebert PA, Benson DW. Effect of positive pressure ventilation on surface tension properties of lung axtracts. Anesthesia 1964; 25: 312-316.
26. Faridy EE, Permutt S, Riley RL. Effect of ventilation on surface forces in excised dogs' lungs. J Appl Physiol 1966; 21: 1453-1462.
27. McClenahan JB, Urtnowski A. Effect of ventilation on surfactant and its turnover rate. J Appl Physiol 1967; 23: 215-230.
28. Forrest JB. The effect of hyperventilation on pulmonary surface activity. Br J Anaesth 1972; 44: 313-319.
29. Wyszogrodski I, Kyei-Aboagye K, Taeusch Jr W, Avery ME. Surfactant inactivation by hyperinflation: conservation by end-expiratory pressure. J Appl Physiol 1975; 38: 461-466.
30. Faridy EE. Effect of ventilation on movement of surfactant in airways. Respir Physiol 1976; 27: 323-334.
31. Tyler DC. Positive end-expiratory pressure: a review. Crit Care Med 1983; 11: 300-308.
32. Veldhuizen RAW, Marcou J, Yao LJ, McGraig L, Ito Y, Lewis JF. Alveolar surfactant aggregate conversion in ventilated normal and injured rabbits. Am J Physiol 1996; 270: L152-L158.
33. Ito Y, Veldhuizen RAW, YYao L, McGraig LA, Bartlett AJ, Lewis JF. Ventilation strategies affect surfactant aggregate conversion in acute lung injury. Am J Resp Crit Care Med 1997; 155: 493-499.
34. Guyton AC, Moffatt DS, Adair TA. Role of alveolar surface tension in transepithelial movement of fluid. Pulmonary Surfactant: from molecular biology to clinical practice. B Robertson, LMG van Golde, JJ Batenburg (eds) Amsterdam, Elsevier, 1983, pp. 339-347.
35. Albert RK, Lakshminarayan S, Hildebrandt J, Kirk W, Butler J. Increased surface tension favors pulmonary edema formation in anesthetized dogs' lungs. J Clin Invest 1979; 63: 1015-1018.
36. Gommers D, Lachmann B. Surfactant therapy: does it have a role in adults? Clin Intern Care 1993; 4: 284-295.
37. Dreyfuss D, Basset G, Soler P, Saumon G. Intermittent positive pressure hyperventilation with high inflation pressures produces pulmonary microvascular injury in rats. Am Res Resp Dis 1985; 132: 880-884.
38. Hallmann M, Merritt TA, Kari A, Bry K. Factors affecting surfactant responsiveness. Ann Med 1991; 23: 693-698.
39. Said SI, Avery ME, Davis RK, Banerjee CM, El-Cohary M. Pulmonary surface activity in induced pulmonary edema. J Clin Invest 1965; 44: 458-464.
40. Lachmann B, Eijking EP, So KL, Gommers D. In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function. Intens Care Med 1994; 20: 6-11.
41. Eijking EP, Gommers D, So KL, de Maat MPM, Lachmann B. A model dor acute respiratory failure induced by tracheal instillation of homologous plasma or protein-rich pulmonary edema fluid. Appl Cardiopulm Pathophysiol 1995; 5: 129-134.
42. Webb HH, Tierney DF. Experimental pulmonary edema due to high intermittent positive pressure ventilation with high inflation pressures. Protection by positive end-expiratory pressure. Am Res Resp Dis 1974; 110: 556-565.
43. Dreyfuss D, Soler P, Basset G, Saumon G. Intermittent positive pressure pulmonary edema respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure. Am Rev Respir Dis 1988; 137: 1159-1164.
44. Roberston B, Curstedt T, Herting E, Sun B, Akino T, Schäfer KP. Alveolar-to-vascular leakage of surfactant protein A in ventilated immature newborm rabbits. Biol Neonate 1995, 68: 185-190.
45. Doyle IR, Nicholas TE, Bersten AD. Serum Surfactant protein-A levels in patients with acute cardiogenic pulmonary edema and adult respiratory distress syndrom. Am J Resp Crit Care Med 1995; 152: 307-317.
46. Winsel K, Lachmann B, Iwainsky H. Changes in lung and liver phospholipids after intra-venous injection of an anti-lung serum, Proceedings of an International Symposium, Varna, Burgaria, May 19-22, 1976. GA Georgiev (ed.) Sofia, 1978, p. 83-96.
47. Swank GM, Deitch EA. Role of the gut in multiple organ failure: Baterial translocation and permeability changes. World J Surg 1996; 20: 411-417.
48. Fink MP. Intestinal Epithelial Hyperpermeability. Year book of Intensive Care and Emergency Medicine JL Vincent, (Ed.) Springer Yerlag, Berlin, Heidelberg, 1997, 658-668.
49. Wolochow H, Hildebrand GJ, Lammanna C. Translocation of microorganisms across the intestinal wall in rats: effect of microbial size and concentration. J Infect Dis 1966; 116: 523.
50. van Saene HKF, Stoutenbeek CC, Stoller JK, Selective decontamination of the digestive tract in the intensive care unit: Current status and future prospects. Crit Care Med 1993; 20: 691-703.
51. Cerra FB, Maddaus MA, Dunn DL et al. Selective gut decontamination reduces nosocomial infections and length of stay but not morality or organ failure in surgical intensive care unit patients. Arch Surg 1992; 127: 163-169.
52. Vandenbroucke-Grauls CMJE, Vandenbroucke JP. Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet 1991; 338: 859-862.
53. Hammond JMJ, Potgieter PD, Saunders GL, Forder AA. Double-blind study of selective decontamination of the digestive tract in intensive care. Lancet 1992; 340: 5-9.
54. Fàbregas N, Torres A, El-Ebiary M et al. Histopathologic and Microbiologic aspects of ventilator-associated pnumonia. Anesthesiology 1996; 84: 760-771.
55. Heyland D, Mandell LA. Gastic colonisation by Gram-negative bacilli and Nosocomial pneumonia in the intensive care unit patient. Evidence for causation. Chest 1992; 101: 187-193.
56. Kollef MH, Schuster DP. Ventilator-associated pneumonia: Clinical considerations. Am J Radiology 1994; 163: 1031-1035.
57. van't Veen A, Gommers D, Lachmann B. Rationale for surfactant therapy in pneumonia. Year book of Intensive Care and Emergency Medicine JL Vincent (ed.) Springer Verlag, Berlin, Heidelberg 1997: 638-653.
58. Büchner H. Arch f Hyg 1988; 8: 145.
59. Tuttle WM, Cannon PR. The passage of bacteria from the lungs into the blood stream. J Infect Dis 1935: 56; 31.
60. Schultz RZ, Warren MF, Drinker CK. The passage of rabbit virulent type II pneumococci from the respiratory tract of rabbits into the lymphatics and blood. J Exp Med 1938; 68: 251-261.
61. Johanson WG, Higuchi JH, Woods DE, Gomez P, Coalson JJ. Dissemination of Pseudomonas aeruginosa during lung infection in hamsters. Am Rev Respir Dis 1985; 132: 358-361.
62. Tilson MD, Bunke MC, Walker Smith GJ et al. Quantitative bacteriology and pathology of the lung in experimental Pseudomonas pneumonia treated with positive end-expiratory pressure (PEEP). Surgery 1977; 82: 133-140.
63. Nahum A, Hoyt J, McKibben A et al. Effect of mechanical ventilation strategy on E. Coli Pneumonia in Dogs. Am Rev Resp Crit Care Med 1996; 153: A530.
64. Michie HR. Metabolism of sepsis and multiple organ failure, World J Surg 1966; 20: 460-464.
65. Schlag G, Redl H. Mediators of injury and Inflammation. World J Surg 1966; 20: 406-410.
66. St John RC, Dorinsky PM. Immunologic therapy for ARDS, septic shock and multiple-organ failure. Chest 1993; 103: 932-943.
67. Jorens PG, Bossaert LL. Cytokine-Networks and ARDS. Year book of Intensive Care and Emergency Medicine JL Vincent (Ed.) Springer Verlag, Berlin, Heidelberg 1997, 83-90.
68. Simon RH, Paine R. Participation of pulmonary alveolar epithelial cells in lung inflammatioh. J Lab Clin Med 1995; 126: 108-118.
69. Lansman JB, Hallam TJ, Rink Tj. Single stretch activated ion channels in vascular endothelial cells as mechanotransducers? Nature 1987; 325: 811-813.
70. Martin DK, Bootcov MR, Campbell TJ, French PW, Breit SN. Human macrophages contain a stretch-sensitive potassium channel that is activated by adherence and cytokines. J Membrane Biol 1995; 147: 305-315.
71. Felix JA, Woodruff ML, Dirksen ER. Stretch increases inoaitol 1, 4, 5-triphosphate concentration in airway epithelial cells. Am J Resp Cell Mol Biol 1996; 14: 296-301.
72. Imai Y, Kawano T, Miyasaka K, Takata M, Imai I, Okuyama K. Inflammatory chemical mediators during conventional mechanical ventilation and during high frequency oscillatory ventilation. Am J Respir Crit Care Med 1994; 150: 1550-1554.
73. Takata M, Abe J, Tanaka H et al. Intraalveolar expression of tumor necrosis factor-alpha gene during conventional and high frequency ventilation. Am J Resp Crit Care Med 1996; 153: A392.
74. von Bethmnn AN, Brasch F, Müller KM, Uhlig S. Barotrauma induced cytokine and eicosanoid-release from the isolated and perfused mouse lung. Am Res Resp Crit Care Med 1996; 153: A529.
75. von Bethmann AN, Brasch F, Müller K, Wendel A, Uhling S. Prolonged hyperventilation is required for release of tumor necrosis factor alpha but not IL-6. Appl Cardiopulm Pathophysiol 1996; 6: 171-177.
76. Berg JT, Fu Z, Breen EC, Tran HC, Mathieu-Costello O, West JB. High lung inflation increases gene expression of extra-cellular matrix components in ling parenchyma. Am J Respir Crit Care Med 1996; 153: A383.
77. Tremblay L, Valenza F, Ribeiro SP, Jingfang L, Slutsky AS. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 1997; 99: 944-952.
78. Narimanbekov IO, Rozycki HJ. Effect of IL-1 blockade on inflammatory manifestations of acute ventilator induced lung injury in a rabbit model. Exp Lund Res 1995; 21: 239-254.
79. Gregory TJ, Steinberg KP, Spragg R et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am Rev Respir Crit Care Med 1997; 155: 1309-1315.
80. Amato MBP, Barbas CSV, Medeiros D et al. Improved survival in ARDS: beneficial effects of a lung protective strategy. Am Rev Respir Crit Care Med 1996; 153: A531.
81. Messent M, Griffiths MJ. The pulmonary physician and critical care. 3. Pharmacotherapy in lung injury. Thorax 1992; 47: 651-656.
82. Van Asbeck BS, van der Wal WA. Role of oxygen radicals and antioxidants in adult respiratory distress syndrome. Potentials in therapy. Resuscitation 1989; 18: S63-83.
83. Christman BW, Bernard GR. Antilipid mediator and antioxidant therapy in adult respiratory distress syndrome. New Horizons 1993; 1: 623-630.
84. Goldstein G, Luce JM, Pharmacologic treatment of the vdult respiratory distress syndrome. Clin Chest Med 1990; 11: 773-787.
85. Hooper RG, Kearl RA. Established ARDS treated with a sustained course of adrenocortical steroids. Chest 1990; 98: 1310-1311.
86. Flick MR, Murray JF. High-dose corticosteroid therapy in the adult respiratory distrss syndrome. JAMA 1984; 251: 1054-1056.
87. Frazee KA, Neidig JA. Ketoconazole to prevent acute respiratory distress syndrome in critically ill patients. Ann Pharmacother 1995; 29: 784-786.
88. A double-blind, prospective randomized clinical trial of ketoconazole, a tromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1995; 21: 1635-1642.
89. Amato MBP, Barbas CSV, Pastore L, Grunauer MA, Magaldi RB, Carvalho CRR. Minimizing barotrauma in ARDS: Protective effects of PEEP and the hazards of driving and plateau pressures. Am Res Resp Crit Care Med 1996; 153: A375.
90. Gommers D, Lachmann B. Surfactant therapy in the adult patient. Curr Opinion Crit Care 1995; 1: 57-67.
91. Lachmann B, Verbrugge S. Liquid Ventilation, Curr Opinion Crit Care 1996; 2: 60-66.